A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
Completed · Phase 2 · Has a placebo group
Conditions studied: Malignant Glioma
In brief
The purpose of this research study is to determine if armodafinil is safe and effective in treating fatigue in patients with malignant gliomas undergoing treatment with radiotherapy plus temodar. Armodafinil is a wakefulness-promoting agent that has been FDA approved for the treatment of excessive daytime sleepiness for a variety of disorders. Armodafinil may also help to reduce radiation-induced fatigue in brain tumor patients.
Key facts
- Study ID
- NCT00766467
- Run by
- Eudocia Quant Lee, MD
- People needed
- 81
- Starts
- 2008-09-01
- Expected to finish
- 2014-07-01
- Last updated by the study team
- 2016-07-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 18 years of age or older
- Histologically confirmed malignant glioma including anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma (WHO grade III/IV), glioblastoma multiforme (WHO grade IV) or gliosarcoma. Patients with a grade II astrocytoma, mixed oligo-astrocytoma or oligodendroglioma who are being treated with irradiation are also eligible
- Scheduled to receive irradiation to a total dose of 50-60 Gy. Patients receiving hyperfractionated radiotherapy are also eligible
- KPS of 70% or greater
- Electrolytes within normal institutional limits: BUN and Creatinine < 2.5 x ULN: AST, ALT, Bilirubin < 2.5 x ULN
- Able to swallow medication
You may not qualify if…
- History of recent cardiac arrhythmia or unstable angina
- Has taken a psychostimulant or a monoamine oxidase inhibitor on a regular basis within the past 30 days
- Clinically significant untreated sleep apnea
- A history of clinically significant cardiac disease, including a history of recent myocardial infarction, history of unstable angina, history of left ventricular hypertrophy, or a history of ischemic ECG changes, chest pain, arrhythmia, or other clinically significant manifestations of mitral valve prolapse in association with use of CNS stimulants (e.g. caffeine, amphetamines, methylphenidate)
- Uncontrolled hypertension, alcohol or drug abuse, severe headaches, glaucoma, narcolepsy, clinically significant untreated sleep apnea, psychotic disorder or Tourette's syndrome
- Patients taking warfarin for anticoagulation are eligible, but monitoring of prothrombin times is suggested as a precaution
- Hemoglobin level of less then 11 g/dl
- Laboratory evidence of hypothyroidism with an elevated TSH concentration in the blood greater than 5.0 mlU/L
- Current treatment or history of psychotic disorder, bipolar disorder, or anxiety disorder
- Patients with a score of > 28 on the Beck depression inventory consistent with severe depression
- Known hypersensitivity to armodafinil or related compounds
- Patients who have been receiving MAO inhibitors during the past 14 days
Where it is running
- UCSD San Diego — La Jolla, California, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.